The United States Food and Drug Administration has granted approval to a new oral weight-loss medication developed by Novo Nordisk, marking an important milestone in the treatment of obesity and significantly intensifying competition with rival drugmaker Eli Lilly. The decision is being seen as a potentially transformative moment for patient access to weight-management therapies, while also offering Novo an opportunity to strengthen its position in the highly competitive US obesity drug market.
On Monday, the US Food and Drug Administration cleared Novo Nordisk’s newly developed weight-loss pill, giving the Danish pharmaceutical company a critical advantage in the race to bring an effective oral obesity drug to market. The approval comes as Novo seeks to recover lost momentum in the United States, where it has faced growing pressure from Eli Lilly and increasing competition from alternative formulations and compounded versions of weight-loss medications.
The newly approved pill contains 25 milligrams of semaglutide, the same active ingredient used in Novo’s injectable weight-loss drug Wegovy and its diabetes treatment Ozempic. The oral version will also be marketed under the Wegovy brand name. Novo already has experience selling an oral semaglutide product for type 2 diabetes, known as Rybelsus, but this approval represents the company’s first oral formulation specifically indicated for weight management.
The FDA’s decision could help spark a turnaround for Novo after a challenging year marked by declining share prices, profit warnings, and slowing sales of injectable Wegovy in the face of fierce competition from Eli Lilly. Investor reaction was swift, with Novo’s US-listed shares jumping around 8 percent in extended trading following the announcement, while shares of Eli Lilly dipped by about 1 percent.
Clinical trial data played a key role in the approval. In a 64-week late-stage study, participants who took 25 milligrams of oral semaglutide once daily experienced an average weight loss of 16.6 percent of their body weight. By comparison, participants who received a placebo lost an average of just 2.7 percent, highlighting the pill’s strong efficacy.
The medication has been approved for chronic weight management in adults who are obese or overweight and have at least one related health condition. This broad indication significantly expands the potential patient base at a time when insurers, employers, and governments are grappling with rapidly rising healthcare costs linked to obesity. Analysts believe the approval could unlock access for tens of millions of patients worldwide, in a global obesity drug market that is expected to be worth around $150 billion annually by the next decade.
Industry experts suggest that oral weight-loss drugs could dramatically increase uptake. Anand Iyer, chief AI officer at telehealth firm Welldoc, noted that patient numbers are likely to surge as new indications are approved and oral options become more widely available. Novo is hoping to capitalize on this trend, particularly in the US market, where it has lost ground to Eli Lilly’s injectable Zepbound, which currently leads in weekly prescription volumes.
Novo executives believe the convenience of a daily pill will attract patients who are hesitant about injections. David Moore, the company’s executive vice president for US operations, said the oral format could significantly boost interest and adoption. He also confirmed that Novo is manufacturing the pill in North Carolina and has been building inventory for some time to ensure sufficient supply once demand ramps up.
Obesity remains a major public health issue in the United States. Government data shows that roughly 40 percent of American adults are obese, and about 12 percent currently report using GLP-1 drugs, according to a recent survey by the health policy research group KFF. While Novo was the first to market with injectable GLP-1 weight-loss drugs, early supply shortages allowed Eli Lilly to gain an edge.
Analysts expect oral medications to play an increasingly important role, potentially accounting for around 20 percent of the weight-loss drug market by 2030. Pills are seen as particularly appealing to patients who prefer less invasive treatment options. However, experts caution that oral drugs are unlikely to fully replace injections. Some patients may continue to favor weekly injections, while others will appreciate the convenience of pills, especially for travel and storage, since pills do not require refrigeration.
Pricing will also be a key factor. Novo said the 1.5-milligram starter dose of the Wegovy pill will be available in early January. Novo and Eli Lilly have agreed to offer starter doses of their weight-loss pills at $149 per month for Medicare and Medicaid beneficiaries, as well as for cash-paying customers through the TrumpRx direct-to-consumer platform. Novo has also recently reduced the cash price of injectable Wegovy to $349 per month, down from $499, although official US list prices for these drugs still hover around $1,000 per month or more.
Despite the optimism, questions remain about whether another semaglutide product can fully resolve Novo’s recent challenges. The oral version must be taken in the morning on an empty stomach, at least 30 minutes before eating, drinking, or taking other oral medications. By contrast, Eli Lilly’s experimental pill does not carry these restrictions, which could influence patient preference once competing products enter the market.
Overall, the FDA approval represents a major strategic win for Novo Nordisk, offering renewed momentum in the obesity treatment space while setting the stage for intensified competition in what is rapidly becoming one of the most lucrative segments of the global pharmaceutical industry.
